Therapeutic antibodies for autoimmunity and inflammation
作者： Andrew C. Chan , Paul J. Carter
DOI: 10.1038/NRI2761
关键词: Immunology 、 Antibody-dependent cell cytotoxicity 、 Antibody 、 Autoimmunity 、 Inflammation 、 First generation 、 Medicine 、 Clinical efficacy
摘要: The development of therapeutic antibodies has evolved over the past decade into a mainstay options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding biology human diseases have been made tremendous benefit to gained first generation antibodies. lessons learnt from these provided foundation discovery future Here we review how key insights obtained complemented by newer antibody engineering technologies are delivering second promise greater clinical efficacy safety.
nature.com
mendeley.com参考文章(164)
M.R. Suresh, A.C. Cuello, C. Milstein, Bispecific monoclonal antibodies from hybrid hybridomas. Methods in Enzymology. ,vol. 121, pp. 210- 228 ,(1986) , 10.1016/0076-6879(86)21019-8
Johan Fransson, Juan C Almagro, Humanization of antibodies. Frontiers in Bioscience. ,vol. 13, pp. 1619- 1633 ,(2008)
Elvin A. Kabat, Sequences of proteins of immunological interest National Institutes of Health. ,(1991)
Pablo Umaña, Joël Jean–Mairet, Radmila Moudry, Hanspeter Amstutz, James E. Bailey, Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity Nature Biotechnology. ,vol. 17, pp. 176- 180 ,(1999) , 10.1038/6179
Robert L Shields, Angela K Namenuk, Kyu Hong, Y Gloria Meng, Julie Rae, John Briggs, Dong Xie, Jadine Lai, Andrew Stadlen, Betty Li, Judith A Fox, Leonard G Presta, None, High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR Journal of Biological Chemistry. ,vol. 276, pp. 6591- 6604 ,(2001) , 10.1074/JBC.M009483200
William F. Dall’Acqua, Kimberly E. Cook, Melissa M. Damschroder, Robert M. Woods, Herren Wu, Modulation of the effector functions of a human IgG1 through engineering of its hinge region. Journal of Immunology. ,vol. 177, pp. 1129- 1138 ,(2006) , 10.4049/JIMMUNOL.177.2.1129
Andrew P. Chapman, Pari Antoniw, Mariangela Spitali, Shauna West, Sue Stephens, David J. King, Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnology. ,vol. 17, pp. 780- 783 ,(1999) , 10.1038/11717
Esohe E. Idusogie, Pin Yee Wong, Leonard G. Presta, Helene Gazzano-Santoro, Klara Totpal, Mark Ultsch, Michael G. Mulkerrin, Engineered Antibodies with Increased Activity to Recruit Complement Journal of Immunology. ,vol. 166, pp. 2571- 2575 ,(2001) , 10.4049/JIMMUNOL.166.4.2571
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. The New England Journal of Medicine. ,vol. 359, pp. 1786- 1801 ,(2008) , 10.1056/NEJMOA0802670
Qian Gong, Qinglin Ou, Shiming Ye, Wyne P. Lee, Jennine Cornelius, Lauri Diehl, Wei Yu Lin, Zhilan Hu, Yanmei Lu, Yongmei Chen, Yan Wu, Y. Gloria Meng, Peter Gribling, Zhonghua Lin, Kathy Nguyen, Thanhvien Tran, Yifan Zhang, Hugh Rosen, Flavius Martin, Andrew C. Chan, Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. Journal of Immunology. ,vol. 174, pp. 817- 826 ,(2005) , 10.4049/JIMMUNOL.174.2.817